Citations

Clear

4802 citation(s) found for "Yu, Jennifer".

IL-10 mRNA Engineered MSCs Demonstrate Enhanced Anti-Inflammation in an Acute GvHD Model
Zhang, Cuiping , Delawary, Mina, Huang, Peng , Korchak, Jennifer A. , Suda, Koji, Zubair, Abba C. , Zubair, Abba C

Mayo Clinic

Cells | November 10, 2021 | Volume: 10 | Issue: 11 | Pages: 3101

10.3390/cells10113101 | PMID 34831324 Get It

Mesenchymal stem cells (MSCs) are used in various studies to induce immunomodulatory effects in clinical conditions associated with immune dysregulation such as graft versus host disease (GvHD). However, most of these clinical trials failed to go beyond early phase 2 studies because of limited efficacy. Various methods have been assessed to increase the potency of MSCs. IL-10 is an anti-inflammatory cytokine that is known to modulate immune responses in GvHD. In this study, we evaluated the feasibility of transfecting IL-10 mRNA to enhance MSC therapeutic potential. IL-10 mRNA engineered MSCs (eMSCs-IL10) maintained high levels of IL-10 expression even after freezing and thawing. IL-10 mRNA transfection did not appear to alter MSC intrinsic characteristics. eMSCs-IL10 significantly suppressed T cell proliferation relative to naïve MSCs in vitro. In a mouse model for GvHD, eMSCs-IL10 induced a decrease in plasma level of potent pro-inflammatory cytokines and inhibited CD4+ and CD8+ T cell proliferation in the spleen. In summary, our studies demonstrate the feasibility of potentiating MSCs to enhance their immunomodulatory effects by IL-10 mRNA transfection. The use of non-viral transfection may generate a safe and potent MSC product for treatment of clinical conditions associated with immune dysregulation such as GvHD.
2-Month-Old Boy With 6-Day History of Increasing Irritability, High-Pitched Cry, and Nonbloody, Nonbilious Vomiting
Colianni, Sonja, Ping, Jennifer, Freese, Deborah K., Fischer, Philip R.

Mayo Clinic

Challenging Cases in Pediatric Diagnosis | November 8, 2021 | Volume: No volume available | Issue: No issue available | Pages: 161-164

10.1542/9781610020176-part07-ch030 Get It

Efficacy and Outcomes of Faecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection in Children with Inflammatory Bowel Disease
Nicholson, Maribeth R. , Alexander, Erin, Ballal, Sonia, Davidovics, Zev, Docktor, Michael , Dole, Michael , Gisser, Jonathan M., Goyal, Alka , Hourigan, Suchitra K. , Jensen, M. Kyle , Kaplan, Jess L. , Kelsen, Judith R. , Khanna, Sahil , Knackstedt, Elizabeth D , Lentine, Jennifer, Lewis, Jeffery D., Michail, Sonia , Mitchell, Paul D. , Patton, Tiffany , Queliza, Karen , Sidhu, Sarah , Solomon, Aliza , Suskind, David L. , Weatherly, Madison, Werlin, Steven L. , Zoeten, Edwin F. de , Kahn, Stacy A. , Group, North American Society of Pediatric Gastroenterology and Nutrition Faecal Microbiota Transplantation Special Interest, Aktay, Nur, Asbah, Imad, Bassett, Mikelle, Brumbaugh, David , Caicedo, Luis A. , Chawla, Anu, Conrad, Máire , Dykes, Chelly Dana, Grzywacz, Kelly, Gulati, Ajay, Gurram, Bhaskar , Hellman, Jenny, Kastl, Art, Mallon, Danny, Pai, Nikhil , Pasternak, Brad , Prozialeck, Josh, Reilly, Norelle R., Russell, George H., Singh, Namita , Small‐Harary, Lesley , Sood, Shilpa , Stumphy, Jessica, Sullivan, Jill M., Syed, Sabeen, Titgemeyer, Cebie, Townsend, Pete, Zheng, Yuhua , Suskind, David L , Alexander, Erin, Kellermayer, Richárd , Kennedy, Melissa A, Oliva‐Hemker, Maria , Group, North American Society of Pediatric Gastroenterology and Nutrition Faecal Microbiota Transplantation Special Interest, Bartlett, Mark, Caicedo, Luis, Gulati, Ajay, Patel, Ashish , Prozialeck, Joshua D. , Sood, Shilpa, Sullivan, Jill

Mayo Clinic

Journal of Crohn's and Colitis | November 8, 2021 | Volume: 16 | Issue: 5 | Pages: 768-777

10.1093/ecco-jcc/jjab202 | PMID 34788420 Get It

Abstract Background Children with inflammatory bowel disease [IBD] are disproportionally affected by recurrent Clostridioides difficile infection [rCDI]. Although faecal microbiota transplantation [FMT] has been used with good efficacy in adults with IBD, little is known about outcomes associated with FMT in paediatric IBD. Methods We performed a retrospective review of FMT at 20 paediatric centres in the USA from March 2012 to March 2020. Children with and without IBD were compared with determined differences in the efficacy of FMT for rCDI. In addition, children with IBD with and without a successful outcome were compared with determined predictors of success. Safety data and IBD-specific outcomes were obtained. Results A total of 396 paediatric patients, including 148 with IBD, were included. Children with IBD were no less likely to have a successful first FMT then the non-IBD affected cohort [76% vs 81%, p = 0.17]. Among children with IBD, patients were more likely to have a successful FMT if they received FMT with fresh stool [p = 0.03], were without diarrhoea prior to FMT [p = 0.03], or had a shorter time from rCDI diagnosis until FMT [p = 0.04]. Children with a failed FMT were more likely to have clinically active IBD post-FMT [p = 0.002] and 19 [13%] patients had an IBD-related hospitalisation in the 3-month follow-up. Conclusions Based on the findings from this large US multicentre cohort, the efficacy of FMT for the treatment of rCDI did not differ in children with IBD. Failed FMT among children with IBD was possibly related to the presence of clinically active IBD.
Factors Associated With Postictal Agitation After Electroconvulsive Therapy
Allen, Nicholas D., Allison, Clayton L., Golebiowski, Raphael, Janowski, John Patrick B., LeMahieu, Allison M., Geske, Jennifer R., Rasmussen, Keith G., Geske, Jennifer R. , LeMahieu, Allison , LeMahieu, Allison M , Geske, Jennifer , Allen, Nicholas D., Allison, Clayton L., Golebiowski, Raphael, Janowski, John Patrick B., Rasmussen, Keith G.

Mayo Clinic

The Journal of ECT | November 5, 2021 | Volume: 38 | Issue: 1 | Pages: 60-61

10.1097/yct.0000000000000807 | PMID 34739422 Get It

Objective This study investigated the occurrence of postictal agitation (PA) in patients undergoing an acute series of electroconvulsive therapy (ECT) and further explored patient and treatment variables associated with PA. Methods Charts were retrospectively searched for patients undergoing an acute series of ECT. Postictal agitation was identified by the administration of a sedative after ECT. Demographic, diagnostic, medication, and ECT variables that could also be associated with PA were collected and accounted for in statistical analysis. Results In this population, 22 of 156 patients experienced PA. Associations that reached statistical significance included sex, weight, active substance use disorder, seizure duration (as observed by motor movements), and waking time. Only seizure duration and waking time maintained significance after multivariable analysis. Conclusions These data identify clinical factors that could help predict PA. Patients with greater weight, male sex, or an active substance use disorder ought to be carefully monitored for PA, and staff in the recovery suite should be especially vigilant about such patients with longer seizures and waking times.
TSC1 loss increases risk for tauopathy by inducing tau acetylation and preventing tau clearance via chaperone-mediated autophagy
Alquezar, Carolina , Schoch, Kathleen M. , Geier, Ethan G., Ramos, Eliana Marisa , Scrivo, Aurora , Li, Kathy H., Argouarch, Andrea R. , Mlynarski, Elisabeth E. , Dombroski, Beth A. , DeTure, Michael , Yokoyama, Jennifer S. , Burlingame, Alma L. , Schellenberg, Gerard D. , Miller, Timothy M. , Miller, Bruce L. , Dombroski, Beth , Dickson, Dennis W , Cuervo, Ana M , Burlingame, Alma L , Schellenberg, Gerard D , Miller, Timothy M , Miller, Bruce L , Kao, Aimee W. , DeTure, Michael , Yokoyama, Jennifer , Alquezar, Carolina , Dickson, Dennis W.

Mayo Clinic

Science Advances | November 5, 2021 | Volume: 7 | Issue: 45 | Pages: No page available

10.1126/sciadv.abg3897 | PMID 34739309 Get It

TSC1/hamartin haploinsufficiency increases risk for tauopathy by promoting tau acetylation and accumulation.
Clinical and Infection Prevention Applications of Severe Acute Respiratory Syndrome Coronavirus 2 Genotyping: an Infectious Diseases Society of America/American Society for Microbiology Consensus Review Document
Greninger, Alexander L. , Bard, Jennifer Dien , Colgrove, Robert C. , Graf, Erin H. , Hanson, Kimberly E. , Hayden, Mary K. , Humphries, Romney M. , Lowe, Christopher F. , Pillai, Dylan R. , Rhoads, Daniel D. , Yao, Joseph D. , Lee, Francesca M, Dien Bard, Jennifer , Humphries, Romney , Hanson, Kimberly , Rhoads, Daniel D , Greninger, Alexander L , Graf, Erin H , Miller, Melissa B.

Mayo Clinic

Journal of Clinical Microbiology | November 3, 2021 | Volume: 60 | Issue: 1 | Pages: No page available

10.1128/jcm.01659-21 | PMID 34731022 Get It

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged into a world of maturing pathogen genomics, with more than 2 million genomes sequenced at the time of writing. The rise of more transmissible variants of concern that impact vaccine and therapeutic effectiveness has led to widespread interest in SARS-CoV-2 evolution.
Discovery of Autoantibodies Targeting Nephrin in Minimal Change Disease Supports a Novel Autoimmune Etiology
Watts, Andrew J.B. , Keller, Keith H. , Lerner, Gabriel, Rosales, Ivy, Collins, A. Bernard, Sekulic, Miroslav , Waikar, Sushrut S. , Chandraker, Anil, Alexander, Mariam P. , Troost, Jonathan P., Chen, Junbo, Fermin, Damian , Yee, Jennifer L., Sampson, Matthew G., Henderson, Joel M., Greka, Anna, Rennke, Helmut G., Weins, Astrid, Henderson, Joel , Riella, Leonardo V , Alexander, Mariam P , Fermin, Damian , Beck, Laurence H , Watts, Andrew J.B. , Keller, Keith H. , Lerner, Gabriel, Rosales, Ivy, Collins, A. Bernard, Sekulic, Miroslav , Waikar, Sushrut S. , Chandraker, Anil, Troost, Jonathan P., Chen, Junbo, Yee, Jennifer L., Sampson, Matthew G., Henderson, Joel M., Greka, Anna, Rennke, Helmut G., Weins, Astrid

Mayo Clinic

Journal of the American Society of Nephrology | November 3, 2021 | Volume: 33 | Issue: 1 | Pages: 238-252

10.1681/asn.2021060794 | PMID 34732507 Get It

Significance Statement Although corticosteroids are an effective first-line therapy for minimal change disease, relapse, steroid dependence, and intolerance are common in this podocytopathy of unknown etiology. The efficacy of B cell–targeted therapies in some patients suggests an autoantibody-mediated etiology. This study describes the novel discovery in both adults and children with minimal change disease of autoantibodies targeting nephrin, a critical component of the podocyte slit diaphragm that ensures integrity of the glomerular filtration barrier. This observation aligns with the established proteinuric effect of antinephrin antibodies demonstrated in animal models. These findings identify an important autoimmune mechanism in a subset of patients with minimal change disease and provide a framework for the application and development of precision medicine strategies in this condition. Background Failure of the glomerular filtration barrier, primarily by loss of slit diaphragm architecture, underlies nephrotic syndrome in minimal change disease. The etiology remains unknown. The efficacy of B cell–targeted therapies in some patients, together with the known proteinuric effect of anti-nephrin antibodies in rodent models, prompted us to hypothesize that nephrin autoantibodies may be present in patients with minimal change disease. Methods We evaluated sera from patients with minimal change disease, enrolled in the Nephrotic Syndrome Study Network (NEPTUNE) cohort and from our own institutions, for circulating nephrin autoantibodies by indirect ELISA and by immunoprecipitation of full-length nephrin from human glomerular extract or a recombinant purified extracellular domain of human nephrin. We also evaluated renal biopsies from our institutions for podocyte-associated punctate IgG colocalizing with nephrin by immunofluorescence. Results In two independent patient cohorts, we identified circulating nephrin autoantibodies during active disease that were significantly reduced or absent during treatment response in a subset of patients with minimal change disease. We correlated the presence of these autoantibodies with podocyte-associated punctate IgG in renal biopsies from our institutions. We also identified a patient with steroid-dependent childhood minimal change disease that progressed to end stage kidney disease; she developed a massive post-transplant recurrence of proteinuria that was associated with high pretransplant circulating nephrin autoantibodies. Conclusions Our discovery of nephrin autoantibodies in a subset of adults and children with minimal change disease aligns with published animal studies and provides further support for an autoimmune etiology. We propose a new molecular classification of nephrin autoantibody minimal change disease to serve as a framework for instigation of precision therapeutics for these patients.
ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition
Kemps, Paul G. , Picarsic, Jennifer , Durham, Benjamin H. , Hélias‐Rodzewicz, Zofia , Hiemcke‐Jiwa, Laura S. , Bos, Cor van den , Noesel, Carel J.M. van , Laar, Jan van , Verdijk, Robert M. , Flucke, Uta , Hogendoorn, Pancras C.W. , Woei-A-Jin, Feng Jung Sherida H. , Beilken, Andreas , Ebinger, Martin , Möhle, Robert, Bornemann, Antje, Wiegering, Verena , Ernestus, Karen, Méry, Tina, Gryniewicz–Kwiatkowska, Olga , Evseev, D. A. , Gaspari, Stefania , Gessi, Marco , Tamburrini, Gianpiero , Héritier, Sébastien , Bonneau‐Lagacherie, Jacinthe, Lamaison, Claire, Farnault, Laure , Fraitag, Sylvie , Jullié, Marie‐Laure , Haroche, Julien , Allotey, Jackie, Madni, Majid, Turner, Kerry , Picton, Susan, Barbaro, Pasquale , Poulin, Alysa, Tam, Ingrid S. , Empringham, Brianna , Whitlock, James A. , Swanson, Amy A. , Suchi, Mariko, Brandt, Jon M., Yaseen, Nabeel R. , Weinstein, Joanna , Eldem, İrem , Sisk, Bryan A. , Sridhar, Vaishnavi , Atkinson, Mandy, Massoth, Lucas R. , Alexandrescu, Sanda , Yeo, Kee Kiat , Petrova‐Drus, Kseniya , Peeke, Stephen , Muñoz-Arcos, Laura , Leino, Daniel , Grier, David D. , Lorsbach, Robert B., Kumar, Ashish R. , Garg, Shipra , Tiwari, Nishant , Schafernak, Kristian T. , Henry, M M , Halteren, Astrid G. S. van , Abla, Oussama , Kumar, Ashish , Hiemcke-Jiwa, Laura , van den Bos, Cor , van Noesel, Carel J M , van Laar, Jan A M , Verdijk, Robert M , Flucke, Uta E , Hogendoorn, Pancras C W , Woei-A-Jin, F J Sherida H , Sciot, Raf , Beilken, Andreas , Feuerhake, Friedrich , Ebinger, Martin , Fend, Falko , Wiegering, Verena , Gryniewicz-Kwiatkowska, Olga , Dembowska-Baginska, Bozenna , Evseev, Dmitry A , Potapenko, Vsevolod , Baykov, Vadim V , Gaspari, Stefania , Rossi, Sabrina , Gessi, Marco , Tamburrini, Gianpiero , Héritier, Sébastien , Donadieu, Jean , Farnault, Laure , Fraitag, Sylvie , Jullié, Marie-Laure , Collin, Matthew , Turner, Kerry , Barbaro, Pasquale M , Tam, Ingrid S , El Demellawy, Dina , Empringham, Brianna , Raghunathan, Aditya , Suchi, Mariko , Weinstein, Joanna L , Eldem, Irem , Sisk, Bryan A , Massoth, Lucas R , Hornick, Jason L , Alexandrescu, Sanda , Yeo, Kee Kiat , Petrova-Drus, Kseniya , Peeke, Stephen Z , Muñoz-Arcos, Laura S , Leino, Daniel G , Grier, David D , Roy, Somak , Kumar, Ashish R , Henry, Michael M , van Halteren, Astrid G S , Abla, Oussama , Diamond, Eli L , Emile, Jean-François , Picarsic, Jennifer L , Schafernak, Kristian , Durham, Benjamin , Wetering, Marianne D. van de , Sciot, Raf , Rossi, Sabrina , Collin, Matthew , Raghunathan, Aditya , Hornick, Jason L. , Diamond, Eli L. , Emile, Jean‐François

Mayo Clinic

Blood | November 2, 2021 | Volume: 139 | Issue: 2 | Pages: 256-280

10.1182/blood.2021013338 | PMID 34727172 Get It

Abstract ALK-positive histiocytosis is a rare subtype of histiocytic neoplasm first described in 2008 in 3 infants with multisystemic disease involving the liver and hematopoietic system. This entity has subsequently been documented in case reports and series to occupy a wider clinicopathologic spectrum with recurrent KIF5B-ALK fusions. The full clinicopathologic and molecular spectra of ALK-positive histiocytosis remain, however, poorly characterized. Here, we describe the largest study of ALK-positive histiocytosis to date, with detailed clinicopathologic data of 39 cases, including 37 cases with confirmed ALK rearrangements. The clinical spectrum comprised distinct clinical phenotypic groups: infants with multisystemic disease with liver and hematopoietic involvement, as originally described (Group 1A: 6/39), other patients with multisystemic disease (Group 1B: 10/39), and patients with single-system disease (Group 2: 23/39). Nineteen patients of the entire cohort (49%) had neurologic involvement (7 and 12 from Groups 1B and 2, respectively). Histology included classic xanthogranuloma features in almost one-third of cases, whereas the majority displayed a more densely cellular, monomorphic appearance without lipidized histiocytes but sometimes more spindled or epithelioid morphology. Neoplastic histiocytes were positive for macrophage markers and often conferred strong expression of phosphorylated extracellular signal-regulated kinase, confirming MAPK pathway activation. KIF5B-ALK fusions were detected in 27 patients, whereas CLTC-ALK, TPM3-ALK, TFG-ALK, EML4-ALK, and DCTN1-ALK fusions were identified in single cases. Robust and durable responses were observed in 11/11 patients treated with ALK inhibition, 10 with neurologic involvement. This study presents the existing clinicopathologic and molecular landscape of ALK-positive histiocytosis and provides guidance for the clinical management of this emerging histiocytic entity.
Insufficient Vitamin C Levels among Adults in the United States: Results from the NHANES Surveys, 2003–2006
Crook, Jennifer , Horgas, Ann L. , Yoon, Saunjoo L. , Grundmann, Oliver , Johnson‐Mallard, Versie, Yoon, Saun-Joo

Mayo Clinic

Nutrients | November 1, 2021 | Volume: 13 | Issue: 11 | Pages: 3910

10.3390/nu13113910 | PMID 34836166 Get It

Vitamin C, well-established in immune function and a key factor in epigenetic inflammatory modifications, is only obtained through consistent dietary intake. Identifying individuals at risk for Vitamin C insufficiency may guide prevention and treatment, however, national surveillance has not been evaluated in the United States since 2006. A descriptive, cross-sectional secondary analysis was performed utilizing data from the 2003–2006 National Health and Nutrition Examination Surveys (NHANES) assessing non-institutionalized adults. Five categories of plasma Vitamin C were delineated: deficiency (<11 μmol/L), hypovitaminosis (11–23 μmol/L), inadequate (23–49 μmol/L), adequate (50–69 μmol/L), and saturating (≥70 μmol/L). Results indicated 41.8% of the population possessed insufficient levels (deficiency, hypovitaminosis, and inadequate) of Vitamin C. Males, adults aged 20–59, Black and Mexican Americans, smokers, individuals with increased BMI, middle and high poverty to income ratio and food insecurity were significantly associated with insufficient Vitamin C plasma levels. Plasma Vitamin C levels reveal a large proportion of the population still at risk for inflammatory driven disease with little to no symptoms of Vitamin C hypovitaminosis. Recognition and regulation of the health impact of Vitamin C support the goal of Nutrition and Healthy Eating as part of the Healthy People 2030.
Re: The Second NINDS/NIBIB Consensus Meeting to Define Neuropathological Criteria for the Diagnosis of Chronic Traumatic Encephalopathy. J Neuropathol Exp Neurol 2021;80(3):210–9
Glass, Jonathan D., Hammers, Jennifer, Omalu, Bennet L, Bieniek, Kevin F. , Crary, John F. , Alosco, Michael E, McKee, Ann C. , Omalu, Bennet I., Dickson, Dennis W. , Stein, Thor D. , Mez, Jesse

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | October 31, 2021 | Volume: 80 | Issue: 10 | Pages: 1007-1010

10.1093/jnen/nlab066 | PMID 34718653 Get It